QualityStocksNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
Gain Therapeutics (NASDAQ: GANX), a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric therapies, has announced the…